key: cord-0888493-kwy2884c
authors: Birabaharan, Morgan; Kaelber, David C.; Orme, Charisse M.; Paravar, Taraneh; Karris, Maile Y.
title: Evaluating risk of bullous pemphigoid after mRNA COVID‐19 vaccination
date: 2022-03-13
journal: Br J Dermatol
DOI: 10.1111/bjd.21240
sha: cd008d6116d14809c1f2197be7bc5677540ec7ce
doc_id: 888493
cord_uid: kwy2884c

‐

consequence of mRNA vaccine technology [1] [2] . In this study, we evaluate the relationship between de novo development of bullous pemphigoid and mRNA COVID-19 vaccination in a large global health research network.

We performed a retrospective cohort study using the TriNetX Analytics Network, a federated health research network that aggregates health records from 63 health-care organizations compromising 70 million patients. We included persons > 18 years of age who between December 15, 2020 and June 15, 2021, who either received first or second dose of Moderna (mRNA-1273) or Pfizer (BNT162b2) (cases) or were diagnosed with acne, seborrheic keratosis, or melanocytic nevi and had no history of COVID-19 vaccination (controls). Diagnoses included in the control cohort were agreed upon by authors to be conditions with no known association with bullous pemphigoid. Multiple diagnoses were included to increase cohort size for robust propensity-matching. Data collection was performed in December 2021 to ensure all persons had an opportunity for 24 weeks of follow-up. New-onset bullous pemphigoid (ICD-10 L12.0) related to mRNA COVID-19 vaccine administration was defined as first-ever diagnosis This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.21240 This article is protected by copyright. All rights reserved.

occurring within 24 weeks. Persons with pemphigus vulgaris (ICD-10 L10.0) were excluded from both cohorts to increase positive predictive value of bullous pemphigoid diagnosis [3] .

We balanced cohorts using 1:1 greedy nearest-neighbor propensity score matching by age, sex, race, ethnicity, neurological disease (Parkinson's, demyelinating disease, other degenerative disorders of the nervous system), psychiatric disease (mood disorders, schizophrenia), cerebral infarction, malignancy, as well as use of DPP4 inhibitors (linagliptin, alogliptin, sitagliptin, saxagliptin), checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, ipilimumab), loop diuretics, and spironolactone. Two dermatologists experienced in evaluating bullous pemphigoid independently agreed on risk factors to be included in the propensity-matched analysis based off literature review [4, 5] . Given persons may have been vaccinated outside of healthcare organizations included in the database, a subgroup analysis was performed against a historical cohort compromised of individuals who received the control diagnoses between January 1, 2020 -December 1, 2020 to assess risk in a population wherein COVID-19 vaccination was not available. Using the matched cohorts, we calculated the relative risk (RR) of first-ever bullous pemphigoid in the 24 weeks after index events in the respective cohorts. All statistical analyses were performed within TriNetX.

We identified 1,540,234 persons who received a dose of the mRNA COVID-19 vaccine. The mean ages in the mRNA COVID-19 vaccine cohort was 54.7 +18.5, 13% were Black, 64% were White, 10% were Hispanic or Latino, and 6% were Asian. Prior to matching, crude incidence of bullous pemphigoid within 24 weeks of mRNA COVID-19 vaccination was 0.004% (57/1,539,720). After 1:1 propensity matching, demographic and clinical characteristics were balanced (standard deviation <0.1). No difference in risk of new-onset bullous pemphigoid was observed among persons receiving the mRNA COVID-19 vaccine within 24-weeks compared to the control cohort (RR 0.77, 95% CI 0.37-1.58) as well as against the historical cohort (RR 0.55, 95% CI 0.30-1.02) ( Table 1) .

Our results suggest mRNA COVID-19 vaccination is not associated with increased risk of newonset bullous pemphigoid. Hopefully, health care professionals may use the findings reported herein to counsel patients experiencing vaccine hesitancy for concerns of de novo autoimmunity.

Our study has limitations to consider when interpreting the results. Firstly, our study reports on the risk of new-onset bullous pemphigoid and does not offer insight as to whether vaccination can flare or cause an exacerbation of the disease. In addition, risk of bullous pemphigoid may differ between first or second dose of mRNA COVID-19 vaccine or by Moderna versus Pfizer vaccination, but was not investigated in this report. Other limitations to consider include the use of population-data, which has inherent misclassification bias from the use of ICD codes. We cannot ascertain completeness of electronic medical records. Lastly, persons may have developed bullous pemphigoid, but not seek care. 

Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination

Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies

Validation of database search strategies for the epidemiological study of pemphigus and pemphigoid

French Study Group for Bullous Diseases. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study

Acknowledgements: This work was supported by grants from the NIH (San Diego Center for